Jubilant Pharmova Q1 Results Live : Jubilant Pharmova declared their Q1 results on 19 Jul, 2024, showcasing impressive financial performance. The company reported a 9.12% year-over-year increase in revenue and a staggering 7432.81% surge in profit.
Comparing to the previous quarter, there was a slight decline of 1.53% in revenue, but the profit soared by 922.7% indicating strong growth momentum.
The Selling, general & administrative expenses saw a marginal decline of 0.38% quarter-on-quarter, while showing a 0.95% increase year-on-year.
Operating income witnessed a remarkable surge of 37013.33% quarter-on-quarter and a substantial increase of 596.75% year-on-year, reflecting efficient cost management and operational performance.
The Earnings Per Share (EPS) for Q1 stood at ₹6.34, marking a significant 1484.54% year-on-year growth.
Investors have shown confidence in Jubilant Pharmova, with a 0.15% return in the last week, 31.06% return in the last 6 months, and a strong 33.28% Year-to-Date return.
With a current market cap of ₹11512.1 Cr and 52-week high/low of ₹780.3 & ₹318.75 respectively, Jubilant Pharmova continues to attract investors’ interest.
Analysts covering the company have unanimously provided a Strong Buy rating, with the consensus recommendation as of 20 Jul, 2024 being Strong Buy, indicating a positive outlook for the company’s future prospects.
Jubilant Pharmova Financials
| Period | Q1 | Q4 | Q-o-Q Growth | Q1 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 1731.7 | 1758.6 | -1.53% | 1586.9 | +9.12% |
| Selling/ General/ Admin Expenses Total | 552.9 | 555 | -0.38% | 547.7 | +0.95% |
| Depreciation/ Amortization | 90.7 | 101 | -10.2% | 89.7 | +1.11% |
| Total Operating Expense | 1175 | 1757.1 | -33.13% | 1507 | -22.03% |
| Operating Income | 556.7 | 1.5 | +37013.33% | 79.9 | +596.75% |
| Net Income Before Taxes | 499.7 | -53.7 | +1030.54% | 25.2 | +1882.94% |
| Net Income | 482.1 | -58.6 | +922.7% | 6.4 | +7432.81% |
| Diluted Normalized EPS | 6.34 | 3.22 | +96.65% | 0.4 | +1484.54% |